Bartonellosis is an infectious disease caused by Bartonella species and is implicated in causing many emerging and re-emerging infections globally. While there are multiple species, the three most common Bartonella species (and the infections they cause) are: Bartonella henselae (Cat Scratch Disease), Bartonella quintana (Trench fever), and Bartonella bacilliformis (Oroya fever).
EUROIMMUN
9 Articles
Food sensitivity Food sensitivity could be caused by increased permeability of the small intestine (as called leaky…
Dengue fever has no specific treatment, but supportive care can help manage the symptoms. Only one vaccine, Dengvaxia® from Sanofi, has been approved by the FDA to prevent severe disease. It is approved for children aged 9 to 16 who live in an endemic area and have previously been infected with DENV as confirmed by a laboratory serological assay.
Rheumatoid Arthritis (RA) is caused when the immune system sends antibodies to attack your joints, leading to joint destruction and disability. While there is no current cure for RA, treatment is possible. Treatment of RA is best done within 3 to 6 months after symptoms start, since permanent joint damage can occur within the first 2 years. This blog will discuss the common antibodies which are tested for in RA diagnosis, and highlight additional uses of antibody testing in RA.
Autoimmune liver diseases (ALD) occur when the immune system turns against liver cells, leading to inflammation. Types of ALD include autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). The detection of specific disease-associated antibodies allows for a differential diagnosis of the culprit ALD, and helps to ensure proper patient treatment. Here we discuss the specific autoantibodies associated with either AIH, PBC, or PSC, as well as the techniques available for their detection.
Less than a year after the World Health Organization (WHO) declared COVID-19 a global pandemic, the authorization of several novel COVID-19 vaccines has created hope for a healthier future. Recent studies have demonstrated that both humoral and cellular immunity play a role in protection from COVID-19. Additionally, the development of novel COVID-19 vaccines requires a look at the immune response in order to determine the effectiveness of the vaccine at preventing infection.
There is a need for continuous monitoring of therapeutic levels of TNF-α inhibitors to promote individualized treatment while affirming that patients receive the most accurate and cost-effective regimen available. With the MabTrack ELISA, clinicians can make effective adjustments based on semi-quantitative results and can facilitate simplified decision-making with their patients for improved long-term response.
SARS-CoV-2, commonly known as the coronavirus disease 2019 (COVID-19) poses an unprecedented public health crisis. While scientists and clinicians worldwide are still working to understand the virus, recent studies show possible onset of autoimmune diseases following COVID-19 infection.
The recent study conducted by De Meyer et al. demonstrated that EUROIMMUN ELISA and SIMOA (single molecule array) platform detected cerebral amyloidosis with equivalent accuracy through measuring the plasma Aβ42/Aβ40 ratio.